A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer.
Conversion surgery
Gastric cancer
HER2
Prognosis
Trastuzumab
Journal
Surgery today
ISSN: 1436-2813
Titre abrégé: Surg Today
Pays: Japan
ID NLM: 9204360
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
30
01
2022
accepted:
15
03
2022
pubmed:
12
5
2022
medline:
30
11
2022
entrez:
11
5
2022
Statut:
ppublish
Résumé
To investigate the clinical indications and prognostic significance of surgical interventions after chemotherapy using trastuzumab-containing regimens for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC). A total of 146 patients with AGC who underwent chemotherapy were enrolled in this retrospective study. Tumors with an immunohistochemistry (IHC) score of 3 + or an IHC score of 2 + plus fluorescence in situ hybridization positivity were defined as HER2-positive AGC. We devised a scoring system for predicting prognosis associated with conversion surgery. Thirty-three patients received trastuzumab-based chemotherapy for HER2-positive tumors. Multivariate analyses identified advanced age, peritoneal dissemination, histologically undifferentiated tumors, and tumor response of progressive disease as independent prognostic factors for a worse prognosis. Twelve patients with HER2-positive AGC underwent conversion surgery. The conversion surgery group of patients with HER2-positive AGC had a better prognosis than the chemotherapy-alone group. A prognostic scoring system based on age, peritoneal dissemination, and histological type was significantly correlated with the presence or absence of conversion surgery and the prognosis of patients with HER2-positive AGC. Our scoring system has the clinical potential to predict prognosis associated with conversion surgery after trastuzumab-containing chemotherapy for patients with HER2-positive AGC.
Identifiants
pubmed: 35543754
doi: 10.1007/s00595-022-02515-6
pii: 10.1007/s00595-022-02515-6
pmc: PMC9700637
doi:
Substances chimiques
Trastuzumab
P188ANX8CK
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1721-1730Subventions
Organisme : The Ministry of Education, Science, Sports, and Culture, Japan.
ID : 19K09200
Informations de copyright
© 2022. The Author(s).
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Gastric Cancer. 2011 Jun;14(2):101-12
pubmed: 21573743
Br J Cancer. 1996 Sep;74(6):975-9
pubmed: 8826869
Eur J Cancer. 2018 Dec;105:41-49
pubmed: 30391779
Ann Surg. 2005 Jan;241(1):27-39
pubmed: 15621988
Ann Oncol. 2005 Feb;16(2):273-8
pubmed: 15668283
Gastric Cancer. 2019 May;22(3):527-535
pubmed: 30386954
BMC Cancer. 2018 Nov 15;18(1):1116
pubmed: 30442107
J Clin Oncol. 2004 Jun 15;22(12):2395-403
pubmed: 15197201
Surg Today. 2021 Nov;51(11):1736-1754
pubmed: 33486610
Ann Gastroenterol Surg. 2018 Jul 10;2(5):339-347
pubmed: 30238074
Ann Oncol. 2008 Sep;19(9):1523-9
pubmed: 18441328
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Histopathology. 2008 Jun;52(7):797-805
pubmed: 18422971
Surg Case Rep. 2020 Sep 24;6(1):219
pubmed: 32970254
Gastric Cancer. 2021 Jan;24(1):1-21
pubmed: 32060757
JAMA Oncol. 2015 Jul;1(4):505-27
pubmed: 26181261
Oncology. 2020;98(11):798-806
pubmed: 32906117
JAMA Oncol. 2017 Apr 01;3(4):524-548
pubmed: 27918777
Clin Cancer Res. 2012 Nov 1;18(21):5992-6000
pubmed: 22977193
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Gastric Cancer. 2016 Apr;19(2):329-338
pubmed: 26643880